Evaluation of SARS-CoV-2 interferon gamma release assay in BNT162b2 vaccinated healthcare workers

PLoS One. 2024 May 10;19(5):e0303244. doi: 10.1371/journal.pone.0303244. eCollection 2024.

Abstract

To predict protective immunity to SARS-CoV-2, cellular immunity seems to be more sensitive than humoral immunity. Through an Interferon-Gamma (IFN-γ) Release Assay (IGRA), we show that, despite a marked decrease in total antibodies, 94.3% of 123 healthcare workers have a positive cellular response 6 months after inoculation with the 2nd dose of BNT162b2 vaccine. Despite the qualitative relationship found, we did not observe a quantitative correlation between IFN-γ and IgG levels against SARS-CoV-2. Using stimulated whole blood from a subset of participants, we confirmed the specific T-cell response to SARS-CoV-2 by dosing elevated levels of the IL-6, IL-10 and TNF-α. Through a 20-month follow-up, we found that none of the infected participants had severe COVID-19 and that the first positive cases were only 12 months after the 2nd dose inoculation. Future studies are needed to understand if IGRA-SARS-CoV-2 can be a powerful diagnostic tool to predict future COVID-19 severe disease, guiding vaccination policies.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral* / blood
  • Antibodies, Viral* / immunology
  • BNT162 Vaccine* / immunology
  • COVID-19 Vaccines / administration & dosage
  • COVID-19 Vaccines / immunology
  • COVID-19* / immunology
  • COVID-19* / prevention & control
  • Female
  • Health Personnel*
  • Humans
  • Immunity, Cellular
  • Immunoglobulin G / blood
  • Immunoglobulin G / immunology
  • Interferon-gamma / blood
  • Interferon-gamma Release Tests*
  • Interleukin-10 / blood
  • Interleukin-10 / immunology
  • Interleukin-6 / blood
  • Interleukin-6 / immunology
  • Male
  • Middle Aged
  • SARS-CoV-2* / immunology
  • Tumor Necrosis Factor-alpha / blood
  • Vaccination

Substances

  • BNT162 Vaccine
  • Antibodies, Viral
  • Interferon-gamma
  • Immunoglobulin G
  • COVID-19 Vaccines
  • Interleukin-10
  • Interleukin-6
  • Tumor Necrosis Factor-alpha

Grants and funding

This research was funded by Fundação para a Ciência e Tecnologia (FCT) (http://www.fct.pt) Special Support Research4Covid, grant number 186. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.